Administration of noncompetitive AMPA receptor antagonist for neuroprotection after traumatic brain injury
OwnerLudmila Belayev, Myron D. Ginsburginventors
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treating traumatic brain injury by the administration of a noncompetitive AMPA receptor antagonist. In certain embodiments, the noncompetitive AMPA receptor antagonist is a 2,3-benzodiazepine derivative. Illustrative 2,3-benzodiazepine derivatives useful according to the invention include (R)-7-acetyl-5(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine.
Claims10
A method for treating traumatic brain injury, comprising the step of administering to a subject in need thereof a therapeutically effective amount talampanel within a therapeutically effective time window.
The method of claim 4, wherein the step of talampanel is initiated about 30 minutes following brain injury.
A pharmaceutical composition comprising a therapeutically effective amount of talampanel and a cyclodextrin carrier vehicle.
Dependencies are inferred from the claim text.